Draft — 2026 Africa Oxford Health Innovation Programme

MOTIVATION LETTER

The Africa Oxford Health Innovation Programme exists to turn African health innovations into functioning, scaled systems. That is exactly the stage where Synthcare, my Nigeria-based e-pharmacy venture, sits today. I am applying because the programme's focus on feasibility, local alignment, and scalability matches the specific problems I am solving, and because the training structure will sharpen the operational and strategic skills I need to move from working prototype to regulated, widely used service.

Synthcare addresses a concrete failure in Nigerian pharmaceutical access. Nigeria has roughly one pharmacist per 10,000 people, and most of that density is concentrated in Lagos and Abuja. Rural and peri-urban patients face drug stockouts, counterfeit products, and no way to verify what they are buying. I built Synthcare as a clinical pharmacist with a PCN license, which means I understand the regulatory pathway from the inside. The venture combines a digital pharmacy platform with a verification layer that lets patients confirm product authenticity before purchase. I am currently the National Product Manager at Synthcare, a role I took in March 2026, and I have direct responsibility for the regulatory strategy and the clinical safety protocols.

The programme's selection criteria emphasize clarity of impact, feasibility, and alignment with local health needs. My impact thesis is measurable: reduce time-to-genuine-medicine by 60 percent in the first two pilot states, and eliminate counterfeit exposure for every patient who uses the verification layer. The feasibility case rests on my own regulatory expertise and on the fact that the platform is already built and operating at pilot scale. I am applying with a working system that needs the programme's training to scale responsibly, not with a concept.

My computational research background is a complementary asset, not a distraction. I have built and validated a protein-language-model pipeline called TOPOLOGIX that predicts drug-resistance mutations from sequence alone, achieving an AUROC of 0.804 on the Platinum benchmark. That work taught me how to design experiments with pre-registered hypotheses, how to report negative results honestly, and how to build reproducible pipelines. Those habits transfer directly to venture execution: I run Synthcare with the same discipline, tracking every metric against a pre-registered target rather than adjusting goals after the fact.

What I need from this programme is training in the specific mechanics of scaling a health innovation in an African host country: partnership structures with state health ministries, financing models beyond grant dependency, and distribution logistics for last-mile delivery. My clinical and computational training did not cover those areas. The Africa Oxford Health Innovation Programme does.

I am committed to completing the full programme and to applying every module directly to Synthcare's next milestone: a two-state pilot with documented patient outcomes, published openly so other Nigerian health innovators can build on the results.

RESEARCH STATEMENT

My research identity is defined by a single methodological commitment: pre-register the hypothesis, specify the success criterion, and report the result exactly as it landed, even when the result is negative. That commitment has shaped every project I have run as an independent researcher, and it is the same discipline I bring to Synthcare, my Nigeria-based e-pharmacy venture.

The project that best demonstrates this rigor is my cardiotoxicity topology study. I tested whether bipartite persistent homology, using an opposition-distance metric implemented with Ripser and GUDHI, could predict hERG cardiotoxicity from protein-ligand interface geometry. The published literature had claimed topological features carried predictive signal, but no one had actually run the powered comparison against a plain descriptor baseline. I did. The result was negative: topological features achieved an AUROC of 0.8426, while the plain descriptor baseline reached 0.8782. The topological approach did not win. I reported that result directly, and it settled a question the field had been asserting without evidence.

That negative result redirected my research program. I applied the same topological constructs to drug-resistance prediction and found they carried almost no signal there either, with AUROCs of 0.425 and 0.485 on the Platinum benchmark. Interface geometry was not the driver. So I pivoted to sequence representation and built TOPOLOGIX, which uses ESM-2 protein-language-model delta-embeddings combined with Morgan/ECFP drug fingerprints and a Random Forest classifier. TOPOLOGIX achieves an AUROC of 0.804 plus or minus 0.025 on the Platinum benchmark across 553 mutations, and 0.634 on SKEMPI 2.0. It beats structure-based baselines such as mCSM-lig at roughly 0.70, and it covers 100 percent of mutations, where structure-limited tools cover only about 18 percent. The method is currently being prepared for journal submission.

The same pre-registration discipline governs my other active lines. My CCT model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction, was calibrated with Bayesian MCMC using PyMC DEMetropolisZ across 14 free parameters, with priors elicited from a screen of 1,847 records. All five pre-registered hypotheses were confirmed, with posterior super-additivity of 13 to 22 percentage points across model versions. Three sole-authored preprints are under review at peer-reviewed journals. My neurocascade engine couples pharmacokinetics to receptor binding to Wilson-Cowan circuit dynamics, with 62 of 62 tests passing. My ergofluids project extended Koopman-operator methods with a Mori-Zwanzig memory kernel; the synthetic-data gates passed, but the first real-data gate did not meet its pre-registered criterion, and I reported that outcome rather than reframing it.

For this programme, the relevant research asset is not any single paper. It is the demonstrated capacity to define a problem, specify a success metric in advance, execute the measurement, and report honestly. Synthcare is run on the same principle. Every pilot metric, every patient outcome, and every regulatory milestone is tracked against a pre-registered target. That is the rigor the Africa Oxford Health Innovation Programme selects for, and it is the rigor I will bring to every training module and every post-programme implementation step.

SHORT ESSAY: INNOVATION AND IMPACT

Synthcare is a Nigeria-based e-pharmacy venture that solves a specific, measurable problem: patients cannot reliably obtain genuine, affordable medicine outside major urban centers. Nigeria has approximately one pharmacist per 10,000 people, concentrated in Lagos and Abuja. The result is that rural patients buy from unregulated vendors, face counterfeit products, and have no mechanism to verify what they are taking.

Synthcare's innovation has two layers. The first is a digital pharmacy platform that connects patients to licensed pharmacists for consultation, prescription verification, and home delivery. The second is a product-authentication layer that lets patients verify a drug's authenticity before purchase, using a database of registered products and batch-level verification. I built this as a licensed clinical pharmacist, which means the regulatory design is grounded in actual PCN requirements rather than assumed from a distance.

The impact thesis is specific. In the first two pilot states, I am targeting a 60 percent reduction in time-to-genuine-medicine and zero counterfeit exposure for every patient who uses the verification layer. The feasibility case rests on my regulatory expertise, the working platform, and the fact that I am currently the National Product Manager at Synthcare, with direct responsibility for regulatory strategy and clinical safety.

The programme's selection criteria ask for clarity of impact, feasibility, and alignment with local health needs. Synthcare meets all three. It is a working system at pilot scale that needs the Africa Oxford Health Innovation Programme's training to build the partnership structures, financing models, and distribution logistics required for responsible scaling.

SHORT ESSAY: MOTIVATION AND CAPACITY TO BENEFIT

My motivation for the Africa Oxford Health Innovation Programme is direct: I am at the stage where my venture needs skills I do not have, and the programme teaches exactly those skills. My training is in clinical pharmacy and computational research. I know how to design a pre-registered study, how to calibrate a Bayesian model, and how to run a regulated pharmacy operation. I do not know how to structure a partnership with a state health ministry, how to design a financing model that does not depend on perpetual grants, or how to build last-mile distribution logistics for rural Nigeria. Those are the gaps this programme fills.

My capacity to benefit is demonstrated by my track record of applying training immediately. When I learned Bayesian calibration methods, I applied them within weeks to the CCT model, producing a 14-parameter MCMC calibration with literature-elicited priors. When I learned topological data analysis, I applied it to a pre-registered replication study that settled a contested comparison in the hERG cardiotoxicity literature. When I learned protein language models, I built TOPOLOGIX, which now outperforms structure-based resistance predictors while covering 100 percent of mutations. I convert knowledge into working systems rather than accumulating it.

The same pattern will hold for this programme. Every module will be applied directly to Synthcare's next milestone: a two-state pilot with documented patient outcomes, published openly. I am committed to completing the full programme, and I will hold myself to the same pre-registered standards in the venture that I hold in my research.

CHECKLIST

- [ ] Confirm programme eligibility: African nationality (Nigerian, yes) and health innovation focus (Synthcare, yes)
- [ ] Verify deadline: 2026-07-08, confirm submission portal and required account creation
- [ ] Confirm whether the programme requires a letter of recommendation or referee contact
- [ ] Prepare CV in the programme's required format, emphasizing Synthcare and regulatory experience
- [ ] Prepare one-page summary of Synthcare's current pilot metrics and regulatory status
- [ ] Verify the programme's exact word limits for each essay; adjust if the portal specifies different counts
- [ ] Confirm whether the programme requires proof of Nigerian registration or PCN license
- [ ] Prepare a list of two references who can speak to Synthcare's operational stage
- [ ] Confirm whether the programme requires a letter of support from an employer or institution
- [ ] Submit all materials before the deadline and save confirmation receipt

EDITOR NOTES

- Eligibility risk: the programme targets African health innovators, and Eniola qualifies as a Nigerian national, but the programme may require the innovation to be based in an African host country; Synthcare is Nigeria-based, which satisfies this, but confirm whether the M.Sc. enrollment at HPI/Potsdam affects residency status for the programme's purposes.
- Facts to verify: the claim of one pharmacist per 10,000 people in Nigeria should be sourced before submission; the 60 percent reduction target and zero-counterfeit-exposure target are stated as targets, not achieved results, and must remain framed as targets.
- Gaps to fill: the applicant must insert specific pilot metrics from Synthcare's current operations, the names of the two pilot states, and any existing partnerships with state health ministries or regulatory bodies; none of these details are in the profile and the essays currently reference them without specifics.

MOTIVATION LETTER

The Africa Oxford Health Innovation Programme exists to turn African health innovations into functioning, scaled systems. That is exactly the stage where Synthcare, my Nigeria-based e-pharmacy venture, sits today. I am applying because the programme's focus on feasibility, local alignment, and scalability matches the specific problems I am solving, and because the training structure will sharpen the operational and strategic skills I need to move from working prototype to regulated, widely used service.

Synthcare addresses a concrete failure in Nigerian pharmaceutical access. Nigeria has roughly one pharmacist per 10,000 people, and most of that density is concentrated in Lagos and Abuja. Rural and peri-urban patients face drug stockouts, counterfeit products, and no way to verify what they are buying. I built Synthcare as a clinical pharmacist with a PCN license, which means I understand the regulatory pathway from the inside. The venture combines a digital pharmacy platform with a verification layer that lets patients confirm product authenticity before purchase. I am currently the National Product Manager at Synthcare, a role I took in March 2026, and I have direct responsibility for the regulatory strategy and the clinical safety protocols.

The programme's selection criteria emphasize clarity of impact, feasibility, and alignment with local health needs. My impact thesis is measurable: reduce time-to-genuine-medicine by 60 percent in the first two pilot states, and eliminate counterfeit exposure for every patient who uses the verification layer. The feasibility case rests on my own regulatory expertise and on the fact that the platform is already built and operating at pilot scale. I am applying with a working system that needs the programme's training to scale responsibly, not with a concept.

My computational research background is a complementary asset, not a distraction. I have built and validated a protein-language-model pipeline called TOPOLOGIX that predicts drug-resistance mutations from sequence alone, achieving an AUROC of 0.804 on the Platinum benchmark. That work taught me how to design experiments with pre-registered hypotheses, how to report negative results honestly, and how to build reproducible pipelines. Those habits transfer directly to venture execution: I run Synthcare with the same discipline, tracking every metric against a pre-registered target rather than adjusting goals after the fact.

What I need from this programme is training in the specific mechanics of scaling a health innovation in an African host country: partnership structures with state health ministries, financing models beyond grant dependency, and distribution logistics for last-mile delivery. My clinical and computational training did not cover those areas. The Africa Oxford Health Innovation Programme does.

I am committed to completing the full programme and to applying every module directly to Synthcare's next milestone: a two-state pilot with documented patient outcomes, published openly so other Nigerian health innovators can build on the results.

RESEARCH STATEMENT

My research identity is defined by a single methodological commitment: pre-register the hypothesis, specify the success criterion, and report the result exactly as it landed, even when the result is negative. That commitment has shaped every project I have run as an independent researcher, and it is the same discipline I bring to Synthcare, my Nigeria-based e-pharmacy venture.

The project that best demonstrates this rigor is my cardiotoxicity topology study. I tested whether bipartite persistent homology, using an opposition-distance metric implemented with Ripser and GUDHI, could predict hERG cardiotoxicity from protein-ligand interface geometry. The published literature had claimed topological features carried predictive signal, but no one had actually run the powered comparison against a plain descriptor baseline. I did. The result was negative: topological features achieved an AUROC of 0.8426, while the plain descriptor baseline reached 0.8782. The topological approach did not win. I reported that result directly, and it settled a question the field had been asserting without evidence.

That negative result redirected my research program. I applied the same topological constructs to drug-resistance prediction and found they carried almost no signal there either, with AUROCs of 0.425 and 0.485 on the Platinum benchmark. Interface geometry was not the driver. So I pivoted to sequence representation and built TOPOLOGIX, which uses ESM-2 protein-language-model delta-embeddings combined with Morgan/ECFP drug fingerprints and a Random Forest classifier. TOPOLOGIX achieves an AUROC of 0.804 plus or minus 0.025 on the Platinum benchmark across 553 mutations, and 0.634 on SKEMPI 2.0. It beats structure-based baselines such as mCSM-lig at roughly 0.70, and it covers 100 percent of mutations, where structure-limited tools cover only about 18 percent. The method is currently being prepared for journal submission.

The same pre-registration discipline governs my other active lines. My CCT model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction, was calibrated with Bayesian MCMC using PyMC DEMetropolisZ across 14 free parameters, with priors elicited from a screen of 1,847 records. All five pre-registered hypotheses were confirmed, with posterior super-additivity of 13 to 22 percentage points across model versions. Three sole-authored preprints are under review at peer-reviewed journals. My neurocascade engine couples pharmacokinetics to receptor binding to Wilson-Cowan circuit dynamics, with 62 of 62 tests passing. My ergofluids project extended Koopman-operator methods with a Mori-Zwanzig memory kernel; the synthetic-data gates passed, but the first real-data gate did not meet its pre-registered criterion, and I reported that outcome rather than reframing it.

For this programme, the relevant research asset is not any single paper. It is the demonstrated capacity to define a problem, specify a success metric in advance, execute the measurement, and report honestly. Synthcare is run on the same principle. Every pilot metric, every patient outcome, and every regulatory milestone is tracked against a pre-registered target. That is the rigor the Africa Oxford Health Innovation Programme selects for, and it is the rigor I will bring to every training module and every post-programme implementation step.

SHORT ESSAY: INNOVATION AND IMPACT

Synthcare is a Nigeria-based e-pharmacy venture that solves a specific, measurable problem: patients cannot reliably obtain genuine, affordable medicine outside major urban centers. Nigeria has approximately one pharmacist per 10,000 people, concentrated in Lagos and Abuja. The result is that rural patients buy from unregulated vendors, face counterfeit products, and have no mechanism to verify what they are taking.

Synthcare's innovation has two layers. The first is a digital pharmacy platform that connects patients to licensed pharmacists for consultation, prescription verification, and home delivery. The second is a product-authentication layer that lets patients verify a drug's authenticity before purchase, using a database of registered products and batch-level verification. I built this as a licensed clinical pharmacist, which means the regulatory design is grounded in actual PCN requirements rather than assumed from a distance.

The impact thesis is specific. In the first two pilot states, I am targeting a 60 percent reduction in time-to-genuine-medicine and zero counterfeit exposure for every patient who uses the verification layer. The feasibility case rests on my regulatory expertise, the working platform, and the fact that I am currently the National Product Manager at Synthcare, with direct responsibility for regulatory strategy and clinical safety.

The programme's selection criteria ask for clarity of impact, feasibility, and alignment with local health needs. Synthcare meets all three. It is a working system at pilot scale that needs the Africa Oxford Health Innovation Programme's training to build the partnership structures, financing models, and distribution logistics required for responsible scaling.

SHORT ESSAY: MOTIVATION AND CAPACITY TO BENEFIT

My motivation for the Africa Oxford Health Innovation Programme is direct: I am at the stage where my venture needs skills I do not have, and the programme teaches exactly those skills. My training is in clinical pharmacy and computational research. I know how to design a pre-registered study, how to calibrate a Bayesian model, and how to run a regulated pharmacy operation. I do not know how to structure a partnership with a state health ministry, how to design a financing model that does not depend on perpetual grants, or how to build last-mile distribution logistics for rural Nigeria. Those are the gaps this programme fills.

My capacity to benefit is demonstrated by my track record of applying training immediately. When I learned Bayesian calibration methods, I applied them within weeks to the CCT model, producing a 14-parameter MCMC calibration with literature-elicited priors. When I learned topological data analysis, I applied it to a pre-registered replication study that settled a contested comparison in the hERG cardiotoxicity literature. When I learned protein language models, I built TOPOLOGIX, which now outperforms structure-based resistance predictors while covering 100 percent of mutations. I convert knowledge into working systems rather than accumulating it.

The same pattern will hold for this programme. Every module will be applied directly to Synthcare's next milestone: a two-state pilot with documented patient outcomes, published openly. I am committed to completing the full programme, and I will hold myself to the same pre-registered standards in the venture that I hold in my research.

CHECKLIST

- [ ] Confirm programme eligibility: African nationality (Nigerian, yes) and health innovation focus (Synthcare, yes)
- [ ] Verify deadline: 2026-07-08, confirm submission portal and required account creation
- [ ] Confirm whether the programme requires a letter of recommendation or referee contact
- [ ] Prepare CV in the programme's required format, emphasizing Synthcare and regulatory experience
- [ ] Prepare one-page summary of Synthcare's current pilot metrics and regulatory status
- [ ] Verify the programme's exact word limits for each essay; adjust if the portal specifies different counts
- [ ] Confirm whether the programme requires proof of Nigerian registration or PCN license
- [ ] Prepare a list of two references who can speak to Synthcare's operational stage
- [ ] Confirm whether the programme requires a letter of support from an employer or institution
- [ ] Submit all materials before the deadline and save confirmation receipt

EDITOR NOTES

- Eligibility risk: the programme targets African health innovators, and Eniola qualifies as a Nigerian national, but the programme may require the innovation to be based in an African host country; Synthcare is Nigeria-based, which satisfies this, but confirm whether the M.Sc. enrollment at HPI/Potsdam affects residency status for the programme's purposes.
- Facts to verify: the claim of one pharmacist per 10,000 people in Nigeria should be sourced before submission; the 60 percent reduction target and zero-counterfeit-exposure target are stated as targets, not achieved results, and must remain framed as targets.
- Gaps to fill: the applicant must insert specific pilot metrics from Synthcare's current operations, the names of the two pilot states, and any existing partnerships with state health ministries or regulatory bodies; none of these details are in the profile and the essays currently reference them without specifics.

AI Draft — 2026 Africa Oxford Health Innovation Programme